The First-In-Human clinical trial will evaluate the safety and tolerability of three doses of OBI-833 (10,30 and 100μg) along with a fixed dose of 100μg OBI-821 adjuvant in a small number of patients (N=26) with late stage gastric, colorectal, breast and lung cancers. Patients will receive a total 10 doses subcutaneously over 24 weeks, and will be evaluated for safety and immune response during the 24 week treatment period and subsequently observed for additional 12 weeks post-treatment. In addition to the standard battery of safety tests, evaluations will also include immunological response, tumor markers and clinical endpoints such as disease or progression free survival (RECIST 1.1).